{"id":"arm-b-durvalumab-plus-selumetinib","safety":{"commonSideEffects":[{"rate":"34%","effect":"Diarrhea"},{"rate":"31%","effect":"Nausea"},{"rate":"28%","effect":"Fatigue"},{"rate":"25%","effect":"Rash"},{"rate":"22%","effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL3301587","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Durvalumab is an anti-PD-L1 antibody, while selumetinib is a MEK inhibitor. This combination targets the MAPK/ERK pathway, which is often dysregulated in cancer cells.","oneSentence":"Inhibits MEK1/2, a key component of the MAPK/ERK signaling pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:14.881Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT02143466","phase":"PHASE1","title":"AZD9291 in Combination With Ascending Doses of Novel Therapeutics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-08-05","conditions":"Advanced Non Small Cell Lung Cancer","enrollment":344},{"nctId":"NCT02546661","phase":"PHASE1","title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2016-12-28","conditions":"Muscle Invasive Bladder Cancer","enrollment":117},{"nctId":"NCT04348045","phase":"PHASE2","title":"Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2020-12-07","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":307},{"nctId":"NCT02117167","phase":"PHASE2","title":"SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2014-04-23","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":999}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MEDI-4736 plus AZD-6244"],"phase":"phase_2","status":"active","brandName":"ARM B - durvalumab plus selumetinib","genericName":"ARM B - durvalumab plus selumetinib","companyName":"GERCOR - Multidisciplinary Oncology Cooperative Group","companyId":"gercor-multidisciplinary-oncology-cooperative-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits MEK1/2, a key component of the MAPK/ERK signaling pathway. Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}